Evidence map›Paper›PMID 41554755›Full record

ArticleNature communications2026

Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates.

Philipp Ochtrop, Anil P Jagtap, Jan G Felber, Simon Vogt, Sarah Herterich, Isabelle Mai, Philipp Cyprys, Saskia Schmitt, Sarah Payer, Annabel Kitowski and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Philipp OchtropTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0000-0003-4498-3136
Anil P JagtapTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Jan G FelberTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0000-0002-5010-9624
Simon VogtTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0009-0004-8865-0055
Sarah HerterichTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Isabelle MaiTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Philipp CyprysTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Saskia SchmittTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0009-0003-1362-9158
Sarah PayerTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Annabel KitowskiTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0000-0002-8001-5928
Swetlana WunderTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Paul MachuiTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Julia BrandmeierTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Natascia LeonardiTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0009-0000-3788-8849
Elizaveta PoliakTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Christian P R HackenbergerChemical Biology Department, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID http://orcid.org/0000-0001-7457-4742
Olivier MarcqTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0000-0001-9097-7146
Dominik SchumacherTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Jonas HelmaTubulis GmbH, IZB, Planegg-Martinsried, Germany.
Annette M VoglTubulis GmbH, IZB, Planegg-Martinsried, Germany.ORCID http://orcid.org/0000-0001-6283-2521
Marc-André KasperTubulis GmbH, IZB, Planegg-Martinsried, Germany. marc.kasper@tubulis.com.ORCID http://orcid.org/0000-0001-7742-7465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in targeted drug delivery, approved Antibody-Drug-Conjugates (ADCs) are still limited by the delivery of a restricted set of payloads with limited modes of action (MOA). Versatile linkers, applicable to functional groups prevalent across diverse pharmacophores are needed to expand this space. We present phosphoramidate-based self-immolative linker-units that facilitate stable attachment in serum and traceless drug release in the target cell of aliphatic and aromatic alcohols. Studies with camptothecins show that stability and release are tunable and that various intracellular trigger events can be exploited to ensure traceless drug delivery. Superior stability, in vivo efficacy, and pharmacokinetics (PK) compared to approved camptothecin ADCs are demonstrated. Moreover, we report targeted delivery of 10 different hydroxy-containing cytotoxins with different intracellular MOAs. In vivo studies with gemcitabine show excellent PK and efficacy, unlocking gemcitabine's full potential and illustrating the ability of the phosphoramidate-based linker system to expand the payload space for ADCs.

Indexed as

AmidesDrug Delivery SystemsImmunoconjugatesPhosphoric AcidsAnimalsCamptothecinCell Line, TumorDeoxycytidineDrug LiberationGemcitabineHumansMiceXenograft Model Antitumor AssaysAmidesCamptothecinDeoxycytidineGemcitabineImmunoconjugatesphosphoramidic acidPhosphoric Acids

Identifiers

PMID41554755
PMCPMC12820277

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.